Previous 10 | Next 10 |
Basking Ridge, NJ, Aug. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare an...
Timber Pharmaceuticals ( NYSE: TMBR ) priced its public offering of 66.67M shares and warrants at an offering price to the public of $0.12/share and associated warrant. The warrants will have an exercise price of $0.12/share, are exercisable immediately on issuance an...
Basking Ridge, NJ, Aug. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare an...
Timber Pharmaceuticals (NYSE:TMBR) said the first four patients were enrolled in a phase 3 trial of its topical drug TMB-001 to treat a moderate to severe forms of congenital ichthyosis (CI). CI are a group of rare genetic skin diseases characterized by dry, thickened and scaling sk...
Pivotal Trial Expected to Enroll More Than 140 Patients With Moderate to Severe Congenital Ichthyosis at Leading Research Centers in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ - ( NewMediaWire ) - June 23, 2022 - Timber Pharmaceuticals, Inc. ("Timber" or the “Co...
The shares of Timber Pharmaceuticals (NYSE:TMBR) added ~56% in the pre-market Tuesday after the dermatology-focused biotech announced that the FDA awarded the Breakthrough Therapy designation for its lead asset TMB-001 in congenital ichthyosis (CI). TMB-001 is a topical formulation ...
- Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial - BASKING RIDGE, NJ - ( NewMediaWire ) - May 31, 2022 - Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on t...
Timber Pharmaceuticals press release (NYSE:TMBR): Q1 GAAP EPS of -$0.05. Grant Revenue of $0.08M (+100.0% Y/Y). Timber ended the first quarter with $13.9 million in cash For further details see: Timber Pharmaceuticals GAAP EPS of -$0.05
Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022 BASKING RIDGE, NJ - ( NewMediaWire ) - May 12, 2022 - Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company...
3 Under $1 Penny Stocks to Watch as April Ends If you’re looking for penny stocks to buy under $1, there are a few things you need to keep in mind. First, penny stocks that trade for less than $1 are often considered more volatile than their higher priced counterparts. That m...
News, Short Squeeze, Breakout and More Instantly...
Timber Pharmaceuticals Inc. Company Name:
TMBR Stock Symbol:
NYSE Market:
WARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that...
WARREN, NJ - ( NewMediaWire ) - November 28, 2023 - Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-...
WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated d...